{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-017275","form_type":"8-K","ticker":"RCKT","cik":"0001281895","company_name":"ROCKET PHARMACEUTICALS, INC.","filed_at":"2026-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.085772+00:00","generated_at":"2026-05-15T02:44:40.244717+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rocket Pharmaceuticals sells Rare Pediatric Disease PRV for $180M, extending cash runway to Q2 2028","bullets":["Enters definitive agreement to sell PRV for $180M in cash; closing subject to HSR antitrust waiting period.","PRV was awarded following FDA accelerated approval of KRESLADI (marnetegragene autotemcel) for LAD-I.","Non-dilutive capital to support cardiovascular pipeline: Danon disease, PKP2-ACM, BAG3-DCM programs.","Cash runway extended into second quarter of 2028, per CEO Gaurav Shah.","PRV program reauthorized in February 2026, reinforcing incentive for rare pediatric disease therapies."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-017275","json":"https://secwatch.observer/filing/0001140361-26-017275.json","markdown":"https://secwatch.observer/filing/0001140361-26-017275.md","text":"https://secwatch.observer/filing/0001140361-26-017275.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/0001140361-26-017275-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/ef20071574_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:44:40.244717+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"20b9666b9f3cf355f2564b0d4f8201d37e9bf88d","claim":"ROCKET PHARMACEUTICALS, INC. entered into PRV APA valued at $180 million (effective 2026-04-26).","evidence_excerpt":"On April 26, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/0001140361-26-017275-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001193125-26-251791","ticker":"KRMN","company_name":"Karman Holdings Inc.","filed_at":"2026-06-01T21:28:29+00:00","headline":"Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds","event_type":"other_material","sec_items":["1.01","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251791","json":"https://secwatch.observer/filing/0001193125-26-251791.json","markdown":"https://secwatch.observer/filing/0001193125-26-251791.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/d117104d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 26, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/0001140361-26-017275-index.htm","comparable_excerpt":"On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm"}},{"accession":"0001213900-26-053524","ticker":"HOVR","company_name":"New Horizon Aircraft Ltd.","filed_at":"2026-05-08T23:59:59+00:00","headline":"New Horizon Aircraft raises ~$20M in registered direct offering of 9.25M shares at $2.15","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-053524","json":"https://secwatch.observer/filing/0001213900-26-053524.json","markdown":"https://secwatch.observer/filing/0001213900-26-053524.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1930021/000121390026053524/0001213900-26-053524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1930021/000121390026053524/ea0289712-8k_newhorizon.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 26, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/0001140361-26-017275-index.htm","comparable_excerpt":"On May 6, 2026, New Horizon Aircraft Ltd. (the “Company”) entered into Securities Purchase Agreements (the “Purchase Agreements”) with certain institutional investors, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Offering”) an aggregate of 9,254,889 our Class A ordinary shares, without par value (the “Shares\", and each Class A ordinary share with no par value in the authorized share structure of the Company, a “Common Share”). The offering price per Share is $2.15, for aggregate gross proceeds to the Company from the Offering of approximately $19.9 million","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1930021/000121390026053524/0001213900-26-053524-index.htm"}},{"accession":"0001104659-26-056482","ticker":"AVTX","company_name":"Avalo Therapeutics, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"Avalo Therapeutics raises ~$405M in public offering; preliminary cash $82M as of March 31","event_type":"other_material","sec_items":["1.01","2.02","7.01","9.01"],"materiality_score":0.9,"calibrated_materiality_score":0.9,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-056482","json":"https://secwatch.observer/filing/0001104659-26-056482.json","markdown":"https://secwatch.observer/filing/0001104659-26-056482.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/0001104659-26-056482-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/tm2613717d1_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 26, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/0001140361-26-017275-index.htm","comparable_excerpt":"On May 5, 2026, Avalo Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, TD Securities (USA) LLC and BofA Securities, Inc., as representatives of the underwriters listed in Schedule A thereto (the “Underwriters”), pursuant to which the Company agreed to issue and sell an aggregate of (a) 19,730,000 shares (the “Shares”) of its common stock, par value $0.001 per share (“Common Stock”), at a price to the public of $17.75 per Share, and (b) pre-funded warrants to purchase up to 1,400,000 shares of Common Stock (the “Pre-Funded Warrants”), at a price to the public of $17.749 per Pre-Funded Warrant, which represents the per share public offering price for the Shares less the $0.001 per share exercise price for each such Pre-Funded Warrant (the “Offering”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1534120/000110465926056482/0001104659-26-056482-index.htm"}},{"accession":"0001683168-26-003551","ticker":"DPLS","company_name":"DarkPulse, Inc.","filed_at":"2026-05-07T23:59:59+00:00","headline":"DarkPulse secures exclusive U.S. Navy license for 3 LADAR patents","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-003551","json":"https://secwatch.observer/filing/0001683168-26-003551.json","markdown":"https://secwatch.observer/filing/0001683168-26-003551.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/866439/000168316826003551/0001683168-26-003551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/866439/000168316826003551/darkpulse_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 26, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/0001140361-26-017275-index.htm","comparable_excerpt":"On May 7, 2026, DarkPulse, Inc., a Delaware corporation (the “ Company ”), entered into an Exclusive Patent License Agreement (Agreement No. NLICENSE-NAWCWDCL-26-027) (the “ License Agreement ”) with the United States of America, as represented by the Secretary of the Navy, acting through the Naval Air Warfare Center Weapons Division (“ NAWCWD ”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/866439/000168316826003551/0001683168-26-003551-index.htm"}},{"accession":"0001185185-26-002273","ticker":"DGAC","company_name":"DISCIPLINED GROWTH ACQUISITION Corp","filed_at":"2026-06-01T20:15:34+00:00","headline":"Disciplined Growth Acquisition Corp. closes $150M IPO on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-26-002273","json":"https://secwatch.observer/filing/0001185185-26-002273.json","markdown":"https://secwatch.observer/filing/0001185185-26-002273.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/dgac8k052926.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 26, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/0001140361-26-017275-index.htm","comparable_excerpt":"A Share Rights Agreement, dated May 26, 2026, by and between the Company and Odyssey Transfer and Trust Company, as rights agent","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2111038/000118518526002273/0001185185-26-002273-index.htm"}},{"accession":"0001493152-26-026603","ticker":"PUBC","company_name":"Purebase Corp","filed_at":"2026-06-01T19:42:27+00:00","headline":"Purebase to receive 20% of net proceeds from CoreTer mining deal; waives corporate opportunities","event_type":"other_material","sec_items":["1.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-026603","json":"https://secwatch.observer/filing/0001493152-26-026603.json","markdown":"https://secwatch.observer/filing/0001493152-26-026603.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1575858/000149315226026603/0001493152-26-026603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1575858/000149315226026603/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 26, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/0001140361-26-017275-index.htm","comparable_excerpt":"On May 26, 2026, Purebase Corporation (the “Company”) entered into a binding Memorandum of Understanding (the “MOU”) with CoreTer LLC, a Nevada limited liability company (“CoreTer”), pursuant to which the Company will be entitled to 20% of the net proceeds received by CoreTer under an Exclusive Mining Option and Development Agreement, dated March 19, 2026, between CoreTer and Dexter Mining LLC.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1575858/000149315226026603/0001493152-26-026603-index.htm"}},{"accession":"0001829126-26-004879","ticker":"SAGU","company_name":"Shreya Acquisition Group","filed_at":"2026-05-11T23:59:59+00:00","headline":"Shreya Acquisition Group closes $110M IPO, 11M units at $10 each on NYSE","event_type":"other_material","sec_items":["1.01","3.02","5.02","5.03","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-004879","json":"https://secwatch.observer/filing/0001829126-26-004879.json","markdown":"https://secwatch.observer/filing/0001829126-26-004879.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/shreyaacq_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 26, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/0001140361-26-017275-index.htm","comparable_excerpt":"Private Units Subscription Agreement, dated May 6, 2026, by and between the Company and the Sponsor, a copy of which is attached as Exhibit 10.4 and incorporated herein by reference","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2083452/000182912626004879/0001829126-26-004879-index.htm"}},{"accession":"0001104659-26-057460","ticker":"CLRB","company_name":"Cellectar Biosciences, Inc.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Cellectar raises ~$35M via stock/warrant offering; reports positive 12-mo Phase 2b WM data","event_type":"other_material","sec_items":["1.01","3.02","8.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-057460","json":"https://secwatch.observer/filing/0001104659-26-057460.json","markdown":"https://secwatch.observer/filing/0001104659-26-057460.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/tm2613728d1_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 26, 2026, Rocket Pharmaceuticals, Inc. (the “Company”) entered into a definitive asset purchase agreement (the “PRV APA”) pursuant to which the Company has agreed to sell a Rare Pediatric Disease Priority Review Voucher (“PRV”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1281895/000114036126017275/0001140361-26-017275-index.htm","comparable_excerpt":"pursuant to an additional securities purchase agreement with certain members of the executive management team of the Company (the “Management Purchase Agreement”","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1279704/000110465926057460/0001104659-26-057460-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}